Skip to main content

Advertisement

SpringerLink
Log in

Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws

  • Short Communication
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

To review the effect of teriparatide as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws (BRONJ), we describe a series of cases of teriparatide therapy for the treatment of BRONJ and serial changes of serum osteoclacin (s-OC) and serum C-terminal telopeptide cross-link of type I collagen (s-CTX).

Introduction

Management of BRONJ is quite challenging and the currently recommended modalities for BRONJ are still suboptimal. For the improvement of bony remodeling, some clinicians advocated bisphosphonate holiday although validity of this drug holiday has been debated so far. Recently, the use of teriparatide was introduced in several cases, but the number of the publication is limited and mostly anecdotal so far.

Method

Bisphosphonate was suspended and teriparatide was given to six patients diagnosed with BRONJ by single bone specialist. Medical record review and interviews were carried out. S-CTX and s-OC were measured at the baseline, 2 months and 3 months later teriparatide therapy. The outcome of the treatment and the change of biochemical markers were compared.

Result

In all six patients, s-OC values were significantly elevated within 2 months after teriparatide treatment and the BRONJ lesions were healed. S-CTX values were also elevated in four patients, whereas those of the rest two patients stayed within minimal change. The change was marginally significant at 3 months.

Conclusion

In terms of the multifactorial etiology of BRONJ, bone formation suppression was noticed in the patients. Based upon this finding, the short-term use of teriparatide might be beneficial to the resolution of BRONJ lesions by improving suppressed bone remodeling.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Lee JJ, Cheng SJ, Jeng JH, Chiang CP, Lau HP, Kok SH (2010) Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head Neck 33(9):1366–1371

    Article  PubMed  Google Scholar 

  2. Kyrgidis A, Antoniades K (2010) Could teriparatide be the treatment for osteonecrosis of the jaws? Head Neck 33(9):1382–1383

    Article  PubMed  Google Scholar 

  3. Harper RP, Fung E (2007) Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 65:573–580

    Article  PubMed  Google Scholar 

  4. Cheung A, Seeman E (2010) Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 363:2473–2474

    Article  CAS  PubMed  Google Scholar 

  5. Barnes GL, Kakar S, Vora S, Morgan EF, Gerstenfeld LC, Einhorn TA (2008) Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J Bone Joint Surg Am 90(Suppl 1):120–127

    Article  PubMed  Google Scholar 

  6. Miller SC, Hunziker J, Mecham M, Wronski TJ (1997) Intermittent parathyroid hormone administration stimulates bone formation in the mandibles of aged ovariectomized rats. J Dent Res 76:1471–1476

    Article  CAS  PubMed  Google Scholar 

  7. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941

    Article  CAS  PubMed  Google Scholar 

  8. Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M (2003) New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 144:2008–2015

    Article  CAS  PubMed  Google Scholar 

  9. Carlson ER, Basile JD (2009) The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surgery 67:85–95

    Article  Google Scholar 

  10. Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporosis Int 19:1613–1620

    Article  CAS  Google Scholar 

  11. Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938

    Article  CAS  PubMed  Google Scholar 

  12. Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199

    Article  CAS  PubMed  Google Scholar 

  13. Kwon YD, Ohe JY, Kim DY, Chung DJ, Park YD (2011) Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers? Clin Oral Implants Res 22:100–105

    Article  PubMed  Google Scholar 

  14. Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR (2009) Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporosis Int 20:2095–2104

    Article  CAS  Google Scholar 

  15. Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397–2410

    Article  PubMed  Google Scholar 

  16. Khosla S, Burr D, Cauley J et al (2008) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 66:1320–1321, author reply 1321-1322

    Article  PubMed  Google Scholar 

  17. Kwon YD, Kim DY, Ohe JY, Yoo JY, Walter C (2009) Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67:2644–2648

    Article  PubMed  Google Scholar 

  18. Pazianas M, Blumentals WA, Miller PD (2008) Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporosis Int 19:773–779

    Article  CAS  Google Scholar 

  19. Lateef M, Baig M, Azhar A (2010) Estimation of serum osteocalcin and telopeptide-C in postmenopausal osteoporotic females. Osteoporosis Int 21:751–755

    Article  CAS  Google Scholar 

  20. Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC (2000) Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 11:295–303

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Oral & Maxillofacial Surgery, Kyung Hee University School of Dentistry, Hoegi-dong, Dongdaenum-ku, Seoul, 130-701, Republic of Korea

    Y.-D. Kwon, D.-W. Lee, B.-J. Choi & J.-W. Lee

  2. Department of Nuclear Medicine, Kyung Hee University School of Medicine, Seoul, Repulbic of Korea

    D.-Y. Kim

Authors
  1. Y.-D. Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D.-W. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B.-J. Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J.-W. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D.-Y. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y.-D. Kwon.

Additional information

Drs. Kwon and D.-W. Lee contributed equally to the work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kwon, YD., Lee, DW., Choi, BJ. et al. Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int 23, 2721–2725 (2012). https://doi.org/10.1007/s00198-011-1882-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-011-1882-9

Keywords

Search

Navigation